Headlines Covid-19 Specialties Trending Feeds Videos

Mashup Score: 5

The Lancet

In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount

  • Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label trial https://t.co/V2VomYT18t Tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%) and less likely to be intubated or die (35% vs 42%). - view on twitter